Goldman Sachs discloses 5.1% stake in Acadia
The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC report beneficial ownership of 4,707,486.16 shares of Acadia Healthcare Company, Inc. common stock, representing 5.1% of the outstanding class.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC report beneficial ownership of 4,707,486.16 shares of Acadia Healthcare Company, Inc. common stock, representing 5.1% of the outstanding class. All voting and dispositive power over these shares is shared, with no sole voting or dispositive authority.
The firms state that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Acadia Healthcare. The filing is made jointly under a written agreement, with both entities represented by an attorney-in-fact.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Goldman Sachs disclose about Acadia Healthcare (ACHC) in this Schedule 13G?
Does Goldman Sachs intend to influence control of Acadia Healthcare (ACHC) with this stake?
Who are the reporting persons in this Acadia Healthcare (ACHC) Schedule 13G filing?
How does the filing describe Goldman Sachs’ role and classification in relation to Acadia Healthcare (ACHC) shares?
AI-generated analysis. How Rhea-AI works. Not financial advice.